Stockscreener 앱 받기
1.77
1.12%
-0.02
시간 외 거래:
1.78
0.01
+0.56%
전일 마감가:
$1.79
열려 있는:
$1.79
하루 거래량:
768.55K
Relative Volume:
1.04
시가총액:
$142.35M
수익:
$63.63M
순이익/손실:
$10.62M
주가수익비율:
35.40
EPS:
0.05
순현금흐름:
$-8.64M
1주 성능:
+1.72%
1개월 성능:
+2.31%
6개월 성능:
+14.94%
1년 성능:
-20.63%
1일 변동 폭
$1.72
$1.795
1주일 범위
$1.72
$1.835
52주 변동 폭
$1.32
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
명칭
Protalix BioTherapeutics Inc.
전화
972 4 988 9488
주소
2 Snunit Street, Science Park PO Box 455, Karmiel
PLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.77 | 143.95M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-17 | 재확인 | Rodman & Renshaw | Buy |
| 2016-04-04 | 개시 | Rodman & Renshaw | Buy |
| 2015-04-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2014-11-12 | 재확인 | R. F. Lafferty | Buy |
| 2014-01-24 | 개시 | R. F. Lafferty | Buy |
| 2012-05-02 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | 재확인 | Oppenheimer | Outperform |
| 2012-04-30 | 다운그레이드 | Auriga | Buy → Hold |
| 2011-10-13 | 개시 | Morgan Joseph | Hold |
| 2011-03-17 | 다운그레이드 | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | 재확인 | Oppenheimer | Outperform |
| 2010-10-14 | 재확인 | UBS | Buy |
| 2009-12-02 | 재확인 | Hapoalim | Outperform |
| 2009-09-22 | 개시 | Canaccord Adams | Buy |
| 2009-09-02 | 개시 | Hapoalim | Outperform |
| 2008-12-01 | 재확인 | Oppenheimer | Outperform |
| 2008-03-11 | 개시 | UBS | Buy |
| 2007-11-20 | 개시 | CIBC Wrld Mkts | Sector Outperform |
모두보기
Protalix BioTherapeutics Inc. 주식(PLX)의 최신 뉴스
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy By Investing.com - Investing.com Nigeria
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline - Proactive financial news
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy - Investing.com
Protalix BioTherapeutics, Inc. Provides 2026 Strategic Update - TradingView — Track All Markets
Protalix BioTherapeutics Letter to Stockholders - Nasdaq
What’s Driving Mazda Limited Stock’s Recent Momentum Key TrendsSector Performance Drivers & Explosive Profit Growth - earlytimes.in
Market Fear: How strong is Protalix BioTherapeutics Inc DE stock earnings growthWeekly Trade Recap & Community Trade Idea Sharing - moha.gov.vn
Protalix BioTherapeutics (AMEX: PLX)Related Research - intelligentinvestor.com.au
Protalix BioTherapeutics (NYSE:PLX) CEO Buys $101,360.00 in Stock - MarketBeat
Bashan Dror, Protalix BioTherapeutics CEO, buys $101k in shares By Investing.com - Investing.com Canada
Protalix BioTherapeutics (PLX) CEO and director reports 56,000-share stock purchase - Stock Titan
PLX: Secarna's Antisense Oligonucleotide Discovery Collaboration - Research Tree
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration - Zacks Small Cap Research
How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Opening Moves & Community Verified Trade Alerts - Улправда
Why Protalix BioTherapeutics Inc. (DE) stock remains stableJuly 2025 Levels & Daily Momentum Trading Reports - ulpravda.ru
Will Protalix BioTherapeutics Inc. (DE) stock outperform Dow JonesWeekly Gains Summary & Entry Point Strategy Guides - DonanımHaber
Can Protalix BioTherapeutics Inc. stock beat analyst upgradesWeekly Gains Summary & Verified Entry Point Detection - Улправда
Institution Moves: Is Protalix BioTherapeutics Inc. stock a contrarian buyBond Market & Community Verified Trade Signals - Улправда
Is Protalix BioTherapeutics Inc. (DE) stock a buy before new product rolloutJuly 2025 Institutional & Reliable Price Breakout Alerts - DonanımHaber
Sentiment Review: Is Protalix BioTherapeutics Inc. stock attractive for hedge fundsJuly 2025 Volume & High Win Rate Trade Tips - Улправда
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3%Still a Buy? - MarketBeat
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3% – Still a Buy? - Defense World
Protalix, Secarna in agreement to develop rare kidney disorder therapies - MSN
Breakout Zone: How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Technicals & AI Forecast for Swing Trade Picks - Улправда
Is Protalix BioTherapeutics Inc. stock a contrarian buy2025 Big Picture & Technical Pattern Based Buy Signals - Улправда
Protalix and Secarna partner to develop rare kidney disease treatments By Investing.com - Investing.com South Africa
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - Finviz
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Protalix BioTherapeutics (PLX) Partners with Secarna for Kidney Disorder Treatments - GuruFocus
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter Into Collaboration and Option Agreement - 富途牛牛
Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development - Proactive financial news
Protalix Partners With Secarna to Jointly Develop Therapies for Rare Renal Indications - marketscreener.com
Protalix and Secarna partner to develop rare kidney disease treatments - Investing.com
Protalix Biotherapeutics and Secarna Pharmaceuticals enter into collaboration and option agreement - marketscreener.com
Protalix BioTherapeutics Earnings Notes - Trefis
Protalix BioTherapeutics (PLX) Price Target Decreased by 10.71% to 12.75 - Nasdaq
Why analysts recommend Protalix BioTherapeutics Inc. (PBDA) stockJuly 2025 Selloffs & Detailed Earnings Play Strategies - Newser
Will Protalix BioTherapeutics Inc. (PBDA) stock rise with strong economy2025 Analyst Calls & Capital Protection Trading Alerts - Newser
How Protalix BioTherapeutics Inc. (DE) stock performs in volatility spikes2025 Short Interest & Growth Oriented Trading Recommendations - Newser
Why global investors buy Protalix BioTherapeutics Inc. (DE) stockMarket Sentiment Summary & Technical Entry and Exit Tips - Newser
Is Protalix BioTherapeutics Inc. (PBDA) stock a contrarian opportunity - Newser
Will Protalix BioTherapeutics Inc. (DE) stock split increase liquidityJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - Newser
Why Protalix BioTherapeutics Inc. (DE) stock attracts wealthy investors2025 Market Trends & Scalable Portfolio Growth Methods - Newser
Is Protalix BioTherapeutics Inc. (DE) stock supported by strong fundamentals2025 Volume Leaders & Technical Confirmation Trade Alerts - Newser
How Protalix BioTherapeutics Inc. (PBDA) stock behaves under inflation pressure2025 Bull vs Bear & Verified Entry Point Detection - Newser
How Protalix BioTherapeutics Inc. (PBDA) stock compares with top peersJuly 2025 Selloffs & Short-Term High Return Ideas - Newser
Protalix BioTherapeutics (PLX) Stock Analysis Report | Financials & Insights - Benzinga
Protalix BioTherapeutics Inc. (PLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):